Does Long-Acting Liposomal Bupivacaine Provide Improved Pain Relief Over Bupivicaine Alone in Carpal Tunnel Release?
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Pain
研究概览
简要总结
Carpal tunnel syndrome is one of the most common surgeries performed per year in the United States, accounting for over 600,000 surgeries. The procedure is commonly performed under light sedation and local anesthesia. Bupivicaine, a long acting local anesthetic, has been used to allow extended pain relief for 8-10 hours after carpal tunnel release. Exparel, a liposomal bupivicaine formulation, has been documented to provide pain relief for up to 72 hours post-operatively. By decreasing post-operative pain through the use of a long-acting local anesthetic, the use of narcotic pain medications may be decreased and patient satisfaction scores may increase.
The purpose of this study is to prospectively compare bupivicaine and liposomal bupivicaine with respect to post-operative pain control, narcotic usage, and patient satisfaction after carpal tunnel release.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 89 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with carpal tunnel syndrome undergoing surgery
排除标准
- •Non english speaking
- •Allergy to bupivacaine or exparel
研究组 & 干预措施
Bupivacaine
Patients will received 0.5% Bupivacaine subcutaneously for local anesthesia during surgery
干预措施: Bupivacaine (Drug)
Exparel
Patients will received Exparel subcutaneously for local anesthesia during surgery
干预措施: Exparel (Drug)
结局指标
主要结局
Pain
时间窗: Starting immediately after surgery and then every 8 hours for 10 days
Pain will be evaluated using an 11-point ordinal scale (0-10)
次要结局
未报告次要终点
